Knowledge and awareness about ADR reporting and pharmacovigilance among medical undergraduates
DOI:
https://doi.org/10.7439/ijbr.v7i5.3315Keywords:
C-Reactive Protein, I, T Ratio, Micro ESR, Neonatal sepsisAbstract
Aim: The present questionnaire survey was conducted with an aim of assessing the knowledge, attitude, and awareness related to pharmacovigilance among the final year students of MBBS and BDS in a teaching hospital. Materials and Methods: To assess the knowledge and awareness about pharmacovigilance and adverse drug reaction (ADR) reporting; a predesigned, structured, close-ended 10 item questionnaire was used. Results: A total of 180 questionnaires were distributed among the health-care professionals. It was found that only 28.88% students comprising 53.8% medical and 46.1% dental students were aware regarding the existence of pharmacovigilance program of India. While, only 47.77% students felt that ADR monitoring centre should be established in every hospital.Conclusion: The results of our study indicate that the majority of the students had a poor knowledge and attitude about pharmacovigilance. It has been advised that all the students (medical and dental) should be trained properly on ADR reporting to improve the current scenario in the pharmacovigilance program of the country.
Downloads
References
Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA 1998; 279:1200-5.
Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997; 277: 301-6.
Hema N, Bhuvana K. Pharmacovigilance: The extent of awareness among the final year students, interns and postgraduates in a government teaching hospital. J Clin Diagn Res 2012; 6:1248-53.
World Health Organization. Requirements for adverse reaction reporting. Geneva, Switzerland: World Health Organization; 1975.
Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: A systematic review of prospective observational studies. Ann Pharmacother 2008; 42:1017-25.
Janaje Munasinghe TM, Singer DR. Costs and prevention of adverse drug reactions. Eur J Intern Med 2001; 12:403-05.
Feely J, Moriarty S, O?Connor P. Stimulating reporting of adverse drug reactions by using a fee. BMJ 1990; 300:22-3.
US Food and Drug Adminstration MedWatch: The FDA Safety Information and Adverse Event Reporting Program. http://www.fda.gov/Safety/MedWatch/default.htm Accessed December22, 2013.
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- An author must submit Copyright form After acceptance of the article.